Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Mar 13, 2025
WATERTOWN, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2024 and provided a corporate update.
Read more at globenewswire.com15.5
-2.91 (-15.83%)
Find more stocks in the Stock Screener
LYRA Latest News and Analysis
2 days ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
8 days ago - ChartmillWhat's going on in today's sessionStay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
8 days ago - ChartmillWhich stocks are moving on Tuesday?Curious about what's happening in today's session? Check out the latest stock movements and price changes.
